Azole derivs. of formula (I) and their salts are new. X,Y,Z = independently N or CR2. R1 = 2-10C alkyl, 3-10C alkenyl, or alkynyl, OR3, 3-8C cycloalkyl, 4-10C cycloalkylalkyl, 5-10C cycloalkyalkenyl or -alkynyl, -(CH2)m-B-(CH2)n-R4- or benzyl. The first 3 gps. and the -(CH2)m-B-(CH2)n-R4 gp. may be monosubstituted by CO2R3, or may have at least 1 H atom replaced by F. The benzyl gp. may be Ph-substd. by 1 or 2 halo, 1-4C alkoxy or NO2 groups. A = an 8-10 membered annelated heterocycle containing up to 9 ring C atoms and opt. substd. by 1-6 R14 and/or -(CH2)n-1-(CHR6-CH2)o-1-R15 gps. L = 1-3C alkanediyl. q = 0 or 1. (I) is e.g. 1-((2-carboxybenzo(b)furan-5-yl) methyl)-2-butyl-4-chloro e-5-hydroxymethyl-imidazole.
USE/ADVANTAGE -As angiotensin (II) converting enzyme inhibitors, useful for treating hypertension, coronary insufficiency, myocardial infarction, coronary hypertrophy, arteriosclerosis, nephropathy, kidney disorders and cerebral vascular disorders, e.g. transitory ischaemic attack and stroke. Dose is 0.1-100 mg/kg., administered intranasally, intravenously, subcutaneously or perorally.
